• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·002742.SZ
Share

Chongqing Jiheng Pharmaceutical Co., Ltd. Stocks

CN¥ 4.07Last Updated 12.10.2026

Issuer Rating

3/7
Performance

Poor

Risk

Limited

Recommendation

Sell

Market Cap

CN¥ 428.32M

CN¥ 4.07
Key Takeaways

Risk factor

Resilient to price shocks

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Chongqing Sansheng Industrial Co.,Ltd. is a Chinese enterprise specializing in the research, development, production, and sale of a diverse range of products, spanning both building materials and chemicals, as well as pharmaceuticals. Within its building materials and chemical segment, the company supplies essential construction inputs such as commercial concrete, water-reducing agents, and expansion agents. These products find extensive application across various large-scale infrastructure projects, including industrial and residential buildings, highways, railways, bridges, tunnels, airports, and water conservancy facilities. Additionally, Sansheng Industrial manufactures sulfuric acid, a key chemical component vital for the production of chemical fertilizers, general industrial chemicals, light industry products, textiles, steel, and water reducer formulations, among other non-fertilizer acidic compounds. The company also maintains a significant presence in the pharmaceutical sector. Its offerings here encompass pharmaceutical intermediates, exemplified by procaine hydrochloride, cefoxitin intermediate, chloramphenicol intermediate, aztreonam intermediate, and orlistat intermediate, which are crucial precursors for antibiotic drugs, anti-hepatitis C treatments, diabetes medications, specific penicillin variants, and cosmetic formulations. Furthermore, Sansheng produces active pharmaceutical ingredients (APIs) such as acetaminophen, cloperidine hydrochloride, levofloxacin mesylate, benoate, and diphenhydramine hydrochloride. Its range of finished pharmaceutical preparations includes compound paracetamol diphenhydramine, clarithromycin sustained-release, diclofenac sodium enteric-coated, and famotidine tablets, designed for diverse therapeutic applications like antipyretic and analgesic effects, antiviral, antibacterial, cough relief, allergy management, and local anesthesia. Beyond these, the company provides a selection of clinically significant drugs, including famotidine, diclofenac sodium, nifedipine, acetaminophen, furosemide, and norfloxacin. Established in 2002, the company was initially known as Chongqing Sansheng Special Building Materials Co., Ltd. before officially adopting its current name, Chongqing Sansheng Industrial Co.,Ltd., in October 2016. Its operations are headquartered in Chongqing, China.

Company Valuation

Greatly overvalued
1/7

Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

13.10.2026 03:00

BofA Identified Three Risks for Apple if SpaceX Becomes a Mobile Carrier

13.10.2026 02:01

Meta has released a new AI model, Muse Wonder, and announced that it has caught up with industry leaders

13.10.2026 01:16

Microsoft could deploy over a million of its own AI chips in 2027, challenging Nvidia

13.10.2026 00:39

Walmart's stock is outperforming luxury stocks. Why might this signal an upcoming Fed rate cut?

12.10.2026 23:19

LVMH fashion and leather sales disappoint in 3Q due to demand slowdown in China

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026